A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell...

por Chiappori, A A, Schreeder, M T, Moezi, M M, Stephenson, J J, Blakely, J, Salgia, R, Chu, Q S, Ross, H J, Subramaniam, D S, Schnyder, J, Berger, M S
Publicado 2012